NASDAQ:ONCO Onconetix (ONCO) Stock Price, News & Analysis $0.06 0.00 (-0.17%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.06 0.00 (-4.03%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Onconetix Stock (NASDAQ:ONCO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Onconetix alerts:Sign Up Key Stats Today's Range$0.06▼$0.0650-Day Range$0.06▼$0.5552-Week Range$0.05▼$21.40Volume1.19 million shsAverage Volume4.08 million shsMarket Capitalization$3.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Read More… Onconetix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreONCO MarketRank™: Onconetix scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Onconetix. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOnconetix has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Onconetix's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.64% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 15.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnconetix does not currently pay a dividend.Dividend GrowthOnconetix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.64% of the float of Onconetix has been sold short.Short Interest Ratio / Days to CoverOnconetix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconetix has recently decreased by 15.56%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News SentimentN/A News SentimentOnconetix has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Onconetix this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for ONCO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Onconetix to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Onconetix insiders have not sold or bought any company stock.Percentage Held by Insiders11.42% of the stock of Onconetix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.89% of the stock of Onconetix is held by institutions.Read more about Onconetix's insider trading history. Receive ONCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconetix and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCO Stock News HeadlinesOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comFive things you need to know today, and calming irrational fearsApril 9, 2025 | bizjournals.comMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by using a secret we tested against every horrible thing that's happened to our financial system since 1991.April 20, 2025 | InvestorPlace (Ad)Onconetix signs non-binding LOI for potential combination with OcuvexApril 9, 2025 | markets.businessinsider.comCincinnati's Onconetix pursuing merger deal with drug development firmApril 8, 2025 | bizjournals.comOnconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.April 8, 2025 | markets.businessinsider.com🌱 Cincinnati's arena debate heats upApril 6, 2025 | msn.comOnconetix executive chairman resigns in latest leadership exit; interim CFO named new top leaderApril 5, 2025 | bizjournals.comSee More Headlines ONCO Stock Analysis - Frequently Asked Questions How have ONCO shares performed this year? Onconetix's stock was trading at $0.63 at the start of the year. Since then, ONCO stock has decreased by 90.6% and is now trading at $0.0595. View the best growth stocks for 2025 here. How were Onconetix's earnings last quarter? Onconetix, Inc. (NASDAQ:ONCO) issued its earnings results on Monday, December, 9th. The company reported ($2.24) EPS for the quarter. When did Onconetix's stock split? Shares of Onconetix reverse split before market open on Tuesday, September 24th 2024. The 1-40 reverse split was announced on Friday, September 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Onconetix? Shares of ONCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Onconetix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconetix investors own include QUALCOMM (QCOM), Zura Bio (ZURA), Capital One Financial (COF), Lincoln National (LNC), Ovid Therapeutics (OVID), Plug Power (PLUG) and Sirius XM (SIRI). Company Calendar Last Earnings12/09/2024Today4/20/2025Next Earnings (Estimated)5/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONCO Previous SymbolNASDAQ:ONCO CIK1782107 Webwww.bwbioinc.com Phone513-620-4101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,410,000.00 Net Margins-2,758.89% Pretax Margin-2,766.32% Return on EquityN/A Return on Assets-48.09% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.05 Sales & Book Value Annual Sales$1.87 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value$3.01 per share Price / Book0.02Miscellaneous Outstanding Shares64,545,000Free Float57,174,000Market Cap$3.84 million OptionableN/A Beta3.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ONCO) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconetix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconetix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.